Table 2.
Therapeutic targets on non-tumor cells in the tumor microenvironment (TME).
| Target molecule | IR700 carrier | TSPC | Cancer | Combination treatment | Tumor model | Ref. |
|---|---|---|---|---|---|---|
| CD25 | Antibody | Anti-CD25-IgG-IR700, Anti-CD25-F(ab′)2-IR700 | Colon cancer | In vitro and in vivo; s.c. | 82 | |
| CD25 | F(ab')2 fragments | Anti-CD25-F(ab')2-IR700 | Colon cancer, lung carcinoma, Prostate cancer | In vitro and in vivo; s.c. | 84 | |
| CD73 | Antibody | αCD73-IR700 | Pancreatic ductal adenocarcinoma(subcutaneous), breast cancer (orthotopic) | PD-1 blockade | In vitro and in vivo; s.c. and ORT | 77 |
| FAP | Antibody | FAP-IR700 | Esophageal squamous cell carcinoma | In vitro and in vivo; s.c. | 76 | |
| FAP | Antibody | FAP-IR700 | Esophageal cancer | 5-FU | In vitro and in vivo; s.c. | 146 |
| Integrin αvβ3 | Nanobody | cRGD-PEG-HSA-IR700 | Ovarian tumor spheroids | In vitro (in 3D cultures) | 79 | |
| Integrin αvβ3 | Nanobody | IR700-PEG-PGlu-cRGDx | Glioblastoma | In vitro and in vivo; s.c. | 80 | |
| Integrin αvβ3 | Nanobody | RGD-8PEG-IR700 | Melanoma spheroids | In vitro (in 3D cultures) | 81 | |
| PDGFRβ | Affibody | Dimeric Z-PDGFRβ-IR700 | Colorectal cancer | In vitro and in vivo; s.c. | 78 | |
| VEGFR-2 | Antibody | DC101-IR700 | Gastric cancer | In vitro and in vivo; s.c. | 56 | |
| VISTA | Antibody | anti-VISTA-IR700 | Colon cancer, lung carcinoma | In vitro and in vivo; s.c. | 85 |
s.c, subcutaneous; ORT, orthotopic